Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01620515 | Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer | completed | Phase 2 | 141 | Nymox CorporationINDUSTRY | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00138918 | Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer | completed | Phase 2 | 20 | University of British ColumbiaOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01087580 | Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02381236 | G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer | completed | Phase 2 | 1 | GenSpera, Inc.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT00049309 | Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer | completed | Phase 2 | 161 | Duke UniversityOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00058084 | Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00303875 | Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight | completed | Phase 2 | 641 | Duke UniversityOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01429064 | Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001 | completed | Phase 2 | 76 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Feb 20, 2017 | clinicaltrials |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 197 | CureVacINDUSTRY | 8 | Feb 17, 2017 | clinicaltrials |
| NCT00035113 | EPO906 Therapy in Patients With Prostate Cancer | completed | Phase 2 | 48 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT01667536 | A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology | completed | Phase 2 | 105 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 8 | Feb 7, 2017 | clinicaltrials |
| NCT00879619 | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | John P. FruehaufOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT02928432 | SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone | completed | Phase 2 | 26 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT00416533 | Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 47 | Wake Forest University Health SciencesOTHER | 0 | Jan 19, 2017 | clinicaltrials |
| NCT01913197 | Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy | terminated | Phase 1 / Phase 2 | 2 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT03013712 | A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer(CARTEPC) | unknown | Phase 1 / Phase 2 | 60 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT00450619 | 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jan 4, 2017 | clinicaltrials |
| NCT01106352 | A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 70 | BayerINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT00686036 | Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy(ZENITH) | terminated | Phase 2 | 17 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 21, 2016 | clinicaltrials |
| NCT00598858 | Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate(2007-5904) | withdrawn | Phase 2 | 0 | John P. FruehaufOTHER | 0 | Dec 8, 2016 | clinicaltrials |
| NCT00659438 | Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer | completed | Phase 2 | 95 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT01750398 | Bipolar Androgen-based Therapy for Prostate Cancer (BAT)(BAT) | completed | Phase 2 | 33 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02645591 | Randomized AmnioFix Study During Radical Prostatectomy | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 22, 2016 | clinicaltrials |
| NCT02906605 | A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 22, 2016 | clinicaltrials |
| NCT00427999 | Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer(INV342) | completed | Phase 2 | 67 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 21, 2016 | clinicaltrials |
| NCT00580970 | Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury | completed | Phase 2 | 73 | Virginia Commonwealth UniversityOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT00946309 | Effects of Sulforaphane on Normal Prostate Tissue(PHASE) | completed | Phase 1 / Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT00081159 | Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases | completed | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 10, 2016 | clinicaltrials |
| NCT02265159 | Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound for the Treatment of Prostate Cancer | unknown | Phase 2 / Phase 3 | 100 | University of ZurichOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT02721784 | Serial mpMRI (Multi Parametric Magnetic Resonance Imaging) Scanning in Prostate Cancer After Androgen Deprivation Therapy and RadioTherapy(SMART) | unknown | Phase 1 / Phase 2 | 10 | University College, LondonOTHER | 1 | Oct 26, 2016 | clinicaltrials |
| NCT00776594 | Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy | completed | Phase 2 | 102 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 21, 2016 | clinicaltrials |
| NCT01558219 | Second-line Chemotherapy in Castration Resistant Prostate Cancer(ProstyII) | completed | Phase 2 | 60 | Tampere University HospitalOTHER | 1 | Oct 21, 2016 | clinicaltrials |
| NCT02002455 | Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma With PET and MRI(Flucipro) | completed | Phase 2 | 26 | Turku University HospitalOTHER_GOV | 1 | Oct 21, 2016 | clinicaltrials |
| NCT02935023 | Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer | unknown | Phase 2 | 47 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT00553878 | Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer(AVIAS) | completed | Phase 2 / Phase 3 | 100 | Canadian Urology Research ConsortiumOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02656563 | Radium 223 Following Intermittent ADT(RAND) | withdrawn | Phase 2 | 0 | Canadian Urology Research ConsortiumOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT00498797 | E3-Hormone Refractory Prostrate Cancer Taxotere Combination | completed | Phase 2 | 86 | SanofiINDUSTRY | 5 | Oct 7, 2016 | clinicaltrials |
| NCT02165020 | Hyaluronic Acid for Hypofractionated Prostate Radiotherapy(RPAH1) | unknown | Phase 2 | 36 | Hospices Civils de LyonOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT01076335 | Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT00852007 | A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1(MUC1) | completed | Phase 1 / Phase 2 | 20 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 15, 2016 | clinicaltrials |
| NCT02621190 | Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs(CARVE) | withdrawn | Phase 2 | 0 | Erasmus Medical CenterOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT01325311 | Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2016 | clinicaltrials |
| NCT00216099 | Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer | completed | Phase 2 | 49 | Christopher Sweeney, MBBSOTHER | 1 | Jul 29, 2016 | clinicaltrials |
| NCT01511536 | Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 38 | SanofiINDUSTRY | 3 | Jul 28, 2016 | clinicaltrials |
| NCT02499848 | Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer | completed | Phase 2 | 18 | Sophiris Bio CorpINDUSTRY | 1 | Jul 27, 2016 | clinicaltrials |
| NCT00196339 | A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients | completed | Phase 2 | 315 | Duramed ResearchINDUSTRY | 2 | Jul 22, 2016 | clinicaltrials |
| NCT02678520 | Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients | withdrawn | Phase 2 | 0 | University of Kansas Medical CenterOTHER | 1 | Jul 22, 2016 | clinicaltrials |
| NCT00031746 | Soy Protein Supplement in Preventing Prostate Cancer in Patients With Elevated Prostate-Specific Antigen Levels | completed | Phase 2 | 26 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT00006359 | Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 63 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 18, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2017source: clinicaltrials